Amgen drops as Q1 report spotlights faster legacy-drug erosion and new overhangs
AMGN•Amgen shares fell after its April 30, 2026 Q1 earnings release highlighted faster-than-expected erosion in several legacy brands from biosimilar competition, despite overall revenue growth to $8.6 billion. Investor attention also centered on disclosed regulatory and tax-related overhangs that could pressure near-term results.
1. What’s moving the stock today
Amgen (AMGN) is trading lower after the company’s April 30, 2026 first-quarter earnings update put renewed focus on near-term headwinds—even as headline results showed growth. Management flagged that 2026 could see accelerated sales erosion as competition increases, with multiple biosimilars launching globally, reinforcing investor concerns about the pace of declines in mature products.
2. The key numbers and the pressure point
In Q1 2026, Amgen reported total revenue of about $8.6 billion, up 6% year over year, with non-GAAP EPS of $5.15, and it raised full-year 2026 guidance (revenue and non-GAAP EPS). The market’s focus today is less on the beat/raise and more on the mix: several established franchises are shrinking quickly under competitive pressure, including material declines in Prolia/Xgeva tied to biosimilar dynamics, which heightens sensitivity to any incremental negative development.
